S
Stephen B. Erickson
Researcher at Mayo Clinic
Publications - 97
Citations - 3535
Stephen B. Erickson is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Kidney disease & Kidney stones. The author has an hindex of 26, co-authored 96 publications receiving 2832 citations. Previous affiliations of Stephen B. Erickson include State University of New York Upstate Medical University.
Papers
More filters
Journal ArticleDOI
Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.
Laurence H. Beck,Fernando C. Fervenza,David M. Beck,Ramon G. Bonegio,Fahim A. Malik,Stephen B. Erickson,Fernando G. Cosio,Daniel C. Cattran,David J. Salant +8 more
TL;DR: M measuring anti-PLA(2)R levels by immunoassay may be a method to follow and predict response to treatment with rituximab in membranous nephropathy.
Journal ArticleDOI
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
Fernando C. Fervenza,Gerald B. Appel,Sean J. Barbour,Brad H. Rovin,Richard A. Lafayette,Nabeel Aslam,Jonathan Ashley Jefferson,Patrick E. Gipson,Dana V. Rizk,John R. Sedor,James F. Simon,Ellen T. McCarthy,Paul Brenchley,Sanjeev Sethi,Carmen Avila-Casado,Heather Beanlands,John C. Lieske,David Philibert,Tingting Li,Tingting Li,Lesley F. Thomas,Dolly F. Green,Luis A. Juncos,Lada Beara-Lasic,Samuel S. Blumenthal,Amy N. Sussman,Stephen B. Erickson,Michelle Hladunewich,Pietro A. Canetta,Lee A. Hebert,Nelson Leung,Jay Radhakrishnan,Heather N. Reich,Samir V. Parikh,Debbie S. Gipson,Dominic K. Lee,Bruno R. da Costa,Peter Jüni,Daniel C Cattran +38 more
TL;DR: Rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months.
Journal ArticleDOI
Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study
Fernando C. Fervenza,Roshini S. Abraham,Stephen B. Erickson,Maria V. Irazabal,Alfonso Eirin,Ulrich Specks,Patrick H. Nachman,Eric J. Bergstralh,Nelson Leung,Fernando G. Cosio,Marie C. Hogan,John J. Dillon,La Tonya J. Hickson,Xujian Li,Daniel C. Cattran +14 more
TL;DR: Four doses of RTX resulted in more effective B cell depletion, but proteinuria reduction was similar to RTX at 1 g every 2 weeks, which could potentially result in undertreatment.
Journal ArticleDOI
Rituximab treatment of idiopathic membranous nephropathy.
Fernando C. Fervenza,Fernando G. Cosio,Stephen B. Erickson,Ulrich Specks,Andrew M. Herzenberg,John J. Dillon,Nelson Leung,Irvin M. Cohen,Daniel N. Wochos,Erik J. Bergstralh,Michelle Hladunewich,Daniel C. Cattran +11 more
TL;DR: Rituximab appears effective in reducing proteinuria in some patients with idiopathic membranous nephropathy but prospective identification of responsive patients was not possible.
Journal ArticleDOI
The Stone Clinic Effect in Patients With Idiopathic Calcium Urolithiasis
Denis H. Hosking,Stephen B. Erickson,Christian J. Van Den Berg,David M. Wilson,Lynwood H. Smith +4 more
TL;DR: It is recommended that specific drug therapy should not be given to patients with idiopathic calcium urolithiasis until the stone clinic effect has been evaluated, and a significant increase in patients who were metabolically inactive at followup was demonstrated.